Please assess the completion status of the following clinical trial:

Trial Title: Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures;~* Men and women 18 years and older;.~* Established indication to PCI according to the guidelines of American Heart Association and American College of Cardiology;~* Native coronary lesion suitable for drug-eluting stent placement and OCT imaging.~Exclusion Criteria:~* Pregnancy and breast feeding mother;~* Co-morbidity with an estimated life expectancy of \< 50 % at 12 months;~* Scheduled major surgery in the next 6 months;~* Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk;~* Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 30 days~* Cardiogenic shock~* Previous subacute or late coronary stent thrombosis~* Known allergy against ticagrelor, or against clopidogrel, or aspirin~* History of major hemorrhage (intracranial, gastrointestinal, etc.)~* Active pathological bleeding~* Acute or chronic hematologic disorder including a Hemoglobin less than 10 g/L or a platelet count less than 10×109/L before procedure~* Any history of Severe renal or hepatic dysfunction (hepatic failure, cirrhosis, portal hypertension and active hepatitis);~* Neutropenia,~* thrombocytopenia;~* Known acute pancreatitis~* Arterial aneurysm, arterial/venous malformation and aorta dissection.~* Culprit lesion within the proximal 10 mm of the right or left coronary artery~* Saphenous vein grafts~* Lesion length \> 30 mm~* Involves a side branch ≥2.0 mm in diameter by visual estimate which requires treatment~* In-stent restenotic lesions~* Thombus-containing lesions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: EXPERIMENTAL): Ticagrelor 90mg tablet, twice daily
- Clopidogrel (Type: EXPERIMENTAL): Clopidogrel 75mg tablet, daily

Based on this trial design, predict the completion outcome and termination type (if applicable).